Frovatriptan

Base Information

• Chemical Name: Frovatriptan
• CAS No.: 158747-02-5
• Molecular Formula: C14H17 N3 O
• Molecular Weight: 243.3
• UNII: H82Q2D5WA7
• DSSTox Substance ID: DTXSID0023080
• Nikkaji Number: J1.042.045H
• Wikipedia: Frovatriptan
• Wikidata: Q410195
• NCI Thesaurus Code: C65772
• RXCUI: 228783
• Pharos Ligand ID: 651G8HLUVTLD
• Metabolomics Workbench ID: 43245
• ChEMBL ID: CHEMBL1279
• Mol file: 158747-02-5.mol

Synonyms:(+)-(R)-5,6,7,8-tetrahydro-6-(methylamino)carbazole-3-carboxamide succinate (1:1), monohydrate;3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;Allegro;Frova;frovatriptan;frovatriptan succinate;Frovelan;SB 209509;VML-251;VML251

Chemical Property of Frovatriptan

Chemical Property:

• Vapor Pressure: 1.01E-10mmHg at 25°C
• Boiling Point: 515.2°Cat760mmHg
• PKA: 16.39±0.40(Predicted)
• Flash Point: 265.4°C
• PSA: 71.90000
• Density: 1.27g/cm³
• LogP: 2.61860
• XLogP3: 1.2
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 2
• Exact Mass: 243.137162174
• Heavy Atom Count: 18
• Complexity: 333

Purity/Quality:

99%, ^*data from raw suppliers

Frovatriptan ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N
• Isomeric SMILES: CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N
• Recent ClinicalTrials: Frovatriptan as a Transitional Therapy in Medication Overuse Headache
• Recent EU Clinical Trials: Comparison between frovatriptan plus different treatment regimens of dexketoprofen (25 mg and 37.5 mg) and frovatriptan alone in the acute treatment of migraine without aura and migraine with aura attacks
• Therapeutic Function: Migraine therapy
• Clinical Use: 5HT1 receptor agonist: Acute relief of migraine
• Drug interactions: Potentially hazardous interactions with other drugs Antidepressants: increased CNS toxicity with citalopram - avoid; blood levels of frovatriptan increased 27-49% by fluvoxamine - avoid; possibly increased serotonergic effects with duloxetine, venlafaxine and SSRIs; increased serotonergic effects with St John’s wort - avoid. Dapoxetine: possible increased risk of serotonergic effects - avoid for 2 weeks after stopping 5HT1 agonists. Ergot alkaloids: increased risk of vasospasm - avoid.